Type 2 Diabetes

A recent retrospective cohort analysis of the ACCORD phase 3 study has revealed a correlation between higher index values and increased mortality risk.

Catch up on the most impactful headlines in T2D from all of 2025 with our Year in Review.

Explore the latest advancements in diabetes technology, including updates on CGMs and insulin pumps, enhancing patient care and management.

GLP-1 medications are revolutionizing treatment for neurological conditions.

Findings link GLP-1 RA use to reduced HCC risk in patients with type 2 diabetes, with benefits partly attributable to avoiding insulin's potential hepatotoxicity.

Catch up with major trial results, key clinician insights, and more.

Shagun Bindlish, MD, emphasizes the urgent need to integrate diabetes and obesity care, addressing their shared metabolic roots for better health outcomes.

The investigational unimolecular GLP-1 and amylin receptor agonist substantially improved weight loss in a phase 2 trial.

Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

A secondary analysis of the J-DOIT3 study highlights previously undertreated factors in the progression of diabetic retinopathy in patients with type 2 diabetes.

The investigative GLP-1/GCG dual receptor agonist led to a higher proportion of participants achieving HbA1c and body weight improvements from baseline.

A post hoc analysis of the PLIS study has highlighted the comparative effectiveness of glucose levels in achieving prediabetes remission.

A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.

Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

New research links sleep-related leg movements to a higher risk of diabetes.

The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.

Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.

The resubmission is based on results from 5 randomized clinical trials in the ONWARDS type 2 diabetes phase 3a program.

Biolinq Shine aims to provide continuous glucose monitoring, as well as sleep and activity data, without requiring injections.

The investigational oral GLP-1 RA showed superiority in glycemic control and weight loss among patients with uncontrolled T2D.

Tirzepatide saw improvements in A1C and body mass index, which were maintained over the 30-week trial and into the 52-week extension study.